Related Experiment Video
Updated: Jan 6, 2026

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
Impact of Risk Stacking on COVID-19-Related Healthcare Utilization: A Real-World Retrospective Cohort Study
Frank R Ernst1, Leah McGrath2, Maya Reimbaeva3
1Pfizer Inc, Cincinnati, OH, USA. Frank.Ernst@Pfizer.com.
Insights
Younger adults with multiple high-risk (HR) comorbidities face greater COVID-19 healthcare risks than older adults or those with immunocompromising conditions. "Risk stacking" of HR conditions significantly increases the likelihood of severe COVID-19 outcomes.
Area of Science:
- Public Health
- Epidemiology
- Health Services Research
Background:
- COVID-19 poses significant health risks, particularly for individuals with underlying health conditions.
- Understanding the cumulative impact of multiple high-risk (HR) conditions, termed 'risk stacking,' is crucial for targeted public health interventions.
- Previous research has focused on individual HR conditions, but the synergistic effects of multiple comorbidities require further investigation.
Purpose of the Study:
- To evaluate the impact of 'risk stacking' on COVID-19-related healthcare resource utilization (HCRU) across different age groups and risk categories.
- To compare HCRU among non-immunocompromised adults (18-49 and 50-64 years) with immunocompromised individuals and those aged 65 years and older.
- To assess the influence of multimorbidity and specific HR categories on COVID-19 HCRU.
Main Methods:
- Utilized Optum Clinformatics® data for a large cohort of adults (n=10,631,427).
- Categorized adults based on CDC-defined HR conditions: HR-Conclusive, HR-Suggestive, Mixed Evidence, and No HR Conditions.
- Analyzed the association between multimorbidity quantities, HR categories, and COVID-19 HCRU (hospitalizations, ED/UC visits, outpatient visits).
Main Results:
- The most prevalent conditions included hypertension (47.4%), obesity (31.9%), chronic heart disease (CHD; 28.1%), and diabetes (DBT; 20.3%).
- COVID-19 HCRU was elevated for combinations like CHD with DBT and CHD with obesity, surpassing that of immunocompromised individuals.
- Multimorbidity across multiple HR categories significantly increased adjusted risk for COVID-19 HCRU across all age groups.
Conclusions:
- Younger adults with multiple non-immunocompromising comorbidities exhibited higher COVID-19 HCRU risk than older adults without multimorbidity or those with immunocompromising conditions.
- 'Risk stacking' of HR comorbidities demonstrably amplifies the risk of severe COVID-19 outcomes and HCRU.
- Broad vaccination and timely treatment access are essential to mitigate severe COVID-19 impacts in all HR populations, irrespective of age.
Introduction:
This study evaluated the impact of "risk stacking" on COVID-19-related hospitalizations, emergency department/urgent care (ED/UC) visits, and outpatient visits among non-immunocompromised individuals aged 18-49 and 50-64 years compared with immunocompromised individuals and those ≥ 65 years.
Methods:
Using Optum Clinformatics® data, adults were assigned to ≥ 1 category based on underlying CDC-categorized high-risk (HR) conditions: HR-Conclusive (from which immunocompromising conditions were separated), HR-Suggestive, Mixed Evidence, No HR Conditions. The impact of multimorbidity quantities and HR categories on COVID-19 healthcare resource utilization (HCRU) was evaluated.
Results:
Overall (n = 10,631,427), the most prevalent conditions were hypertension (HTN; 47.4%), obesity/overweight (31.9%), chronic heart disease (CHD; 28.1%), and diabetes (DBT; 20.3%). COVID-19 HCRU was higher for CHD with DBT, CHD with obesity, and HTN with obesity than for immunocompromised individuals and highest among those aged ≥ 65 years. Multimorbidity across multiple HR categories resulted in greater adjusted risk for COVID-19 HCRU for all ages.
Conclusion:
Younger adults with multiple non-immunocompromising comorbidities had greater risk of COVID-19-related HCRU than those with immunocompromising conditions or ≥ 65 years without multimorbidity. Stacking HR comorbidities increased the risk of HCRU. Ensuring broad vaccination and treatment recommendations and access is critical to mitigating severe COVID-19 in HR groups of any age.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Relative Risk
Bias in Epidemiological Studies
Causality in Epidemiology
Confounding in Epidemiological Studies
Hazard Ratio
For example, in a clinical trial...

